B-859-35, a new drug with anti-tumor activity reverses multi-drug resistance

✍ Scribed by Johann Hofmann; Florian Ueberall; Alexander Egle And; Hans Grunicke

• Book ID: 102867602
• Publisher: John Wiley and Sons
• Year: 1991
• Tongue: French
• Weight: 569 KB
• Volume: 47
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910470614

✦ Synopsis

It has previously been shown that 6-859-35 ((-)-3-methyl-5-3-(4,4-diphenyl-I -piperidinyl)-propyl-I ,4-dihydro-2,6-d i m e t h y 1-44 3-n i tro p h en y I)-p y rid i ne-3,5-d i car boxylate-hydrochloride) exerts a selective carcinostatic effect on some tumors. In order to evaluate whether the anti-cancer activity of 6-859-35 can be modulated, we combined the new drug with several established anti-tumor drugs. A combination of 6-859-35 with VP-16 (etoposide) in MDR(multidrug-resistant-gene)-expressing Walker rat carcinoma cells shows synergism. A combination of 6-859-35 with doxorubicin results in stronger synergism than verapamiVdoxorubicin, especially at low concentrations of 6-859-35. The resistance of rndrl(hurnan multi-drug-resistance-genehexpressing human HeLa KB-8-5 cells to doxorubicin can be reversed with nontoxic or weakly toxic concentrations of 6-859-35 to the sensitivity of the parent KB-3-1 cells. The finding that an antitumor drug is able to reverse multi-drug resistance makes 6-859-35 an interesting drug for cancer treatment.